G. Lefebvre
About
G. Lefebvre is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, G. Lefebvre has authored 19 papers receiving a total of 114 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Otorhinolaryngology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Lefebvre's work include Cancer Immunotherapy and Biomarkers (9 papers), Head and Neck Cancer Studies (8 papers) and Lung Cancer Treatments and Mutations (5 papers). G. Lefebvre is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Head and Neck Cancer Studies (8 papers) and Lung Cancer Treatments and Mutations (5 papers). G. Lefebvre collaborates with scholars based in France, United States and Switzerland. G. Lefebvre's co-authors include Jessica R. Bauman, Tanguy Y. Seiwert, Caroline Even, Jérôme Fayette, Robert Zerbib, Sébastien Salas, Esma Saâda-Bouzid, Marshall R. Posner, Roger B. Cohen and Agnès Boyer-Chammard and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
In The Last Decade
G. Lefebvre
17 papers receiving 114 citations
Peers
G. Lefebvre
Carly Reeder United States
Colleen Maher United States
Zhanxiong Luo China
Behzad Bidadi United States
Sophie Wildsmith United Kingdom
Amanda J. Rode United States
Jagdish Shetty United States
Michaela K. Keck United States
Gustavo Dix Junqueira Pinto Brazil
Hui Yi Chew Australia
Citations per year, relative to G. Lefebvre G. Lefebvre (= 1×)
peers
Carly Reeder
Countries citing papers authored by G. Lefebvre
Since
Specialization
Citations
This map shows the geographic impact of G. Lefebvre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Lefebvre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Lefebvre more than expected).
Fields of papers citing papers by G. Lefebvre
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by G. Lefebvre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Lefebvre. The network helps show where G. Lefebvre may publish in the future.
Co-authorship network of co-authors of G. Lefebvre
This figure shows the co-authorship network connecting the top 25 collaborators of G. Lefebvre. A scholar is included among the top collaborators of G. Lefebvre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Lefebvre. G. Lefebvre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Aupérin, Anne, Christian Borel, G. Lefebvre, et al.. (2025). NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.. Journal of Clinical Oncology. 43(17_suppl).
2.
Fayette, Jérôme, Aron Popovtzer, Martin Förster, et al.. (2025). Dose expansion data from iintune-1, a phase 1/2 study of the STING agonist dazostinag plus pembrolizumab as first-line (1L), in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RM-SCCHN).. Journal of Clinical Oncology. 43(16_suppl). 6020–6020.
3.
Guigay, J., Emmanuel Chamorey, G. Lefebvre, et al.. (2021). Observational, prospective, phase 4 study in patients with first‐line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum‐based therapy: DIRECT . Cancer Reports. 5(2). e1467–e1467.
4.
Even, Caroline, Amaury Daste, Jérôme Fayette, et al.. (2020). 917MO TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis. Annals of Oncology. 31. S662–S662.
5.
Tresch, Emmanuelle, et al.. (2020). Évaluation des interactions médicamenteuses chez des patients traités pour un cancer pulmonaire ou digestif. Bulletin du Cancer. 107(11). 1108–1117.
6.
Fayette, Jérôme, Jessica R. Bauman, Sébastien Salas, et al.. (2020). 81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from a phase II trial. Annals of Oncology. 31. S1450–S1450.
7.
Cohen, Roger B., Jessica R. Bauman, Sébastien Salas, et al.. (2020). Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.. Journal of Clinical Oncology. 38(15_suppl). 6516–6516.
8.
Cohen, Romain, G. Lefebvre, Marshall R. Posner, et al.. (2019). Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data. Annals of Oncology. 30. v460–v460.
9.
Fayette, Jérôme, Laurence Digue, Céline Ségura‐Ferlay, et al.. (2019). Buparlisib (BKM120) in refractory head and neck squamous cell carcinoma harbouring or not a PI3KCA mutation: A phase II multicenter trial. Annals of Oncology. 30. v455–v455.
10.
Even, Caroline, Amaury Daste, Esma Saâda-Bouzid, et al.. (2019). A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): Interim analysis on 199 patients—The TOPNIVO study on behalf of the GORTEC and the Unicancer Head & Neck Group.. Journal of Clinical Oncology. 37(15_suppl). 6032–6032.
11.
Even, Caroline, Amaury Daste, Esma Saâda-Bouzid, et al.. (2018). TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC. Annals of Oncology. 29. viii380–viii380.
12.
Lefebvre, G., Emmanuelle Tresch‐Bruneel, Marie‐Cécile Le Deley, et al.. (2018). Prevalence of herbal medicine (HM) use among breast cancer patients treated with chemotherapy, hormone therapy, or targeted therapy.. Journal of Clinical Oncology. 36(15_suppl). e13108–e13108.
13.
Bricout, Hélène, Olivier Le Rouzic, F. Mouawad, et al.. (2018). Compared characteristics of current vs. past smokers at the time of diagnosis of a first-time lung or head and neck cancer: a cross-sectional study. BMC Cancer. 18(1). 372–372.
14.
Cohen, Roger B., Jérôme Fayette, Marshall R. Posner, et al.. (2018). Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy. Cancer Research. 78(13_Supplement). CT158–CT158.
15.
Fayette, Jérôme, G. Lefebvre, Marshall R. Posner, et al.. (2018). Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Annals of Oncology. 29. viii374–viii374.
16.
Bricout, Hélène, et al.. (2017). Determinants of smoking status of patients with lung or head and neck cancer, at diagnosis and one year after. PA2997–PA2997.
17.
Tardy, Magalie P., J. Doyen, Amaury Daste, et al.. (2017). Characteristics of very long responder to maintenance cetuximab after a platinum-cetuximab based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinomas (RM HNSCC).. Journal of Clinical Oncology. 35(15_suppl). e17524–e17524.
18.
Fayette, Jérôme, Laurence Digue, Céline Ferlay, et al.. (2016). PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy. Annals of Oncology. 27. vi331–vi331.
19.
Fournier, Charles, Véronique Christophe, M. Reich, et al.. (2015). Selection of ultimately ill cancer patients able to fulfill a questionnaire: Identification of inherent biases. Bulletin du Cancer. 102(9). 730–736.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carly Reeder Breakdown of academic impact, for papers by Colleen Maher Breakdown of academic impact, for papers by Zhanxiong Luo Breakdown of academic impact, for papers by Behzad Bidadi Breakdown of academic impact, for papers by Sophie Wildsmith Breakdown of academic impact, for papers by Amanda J. Rode Breakdown of academic impact, for papers by Jagdish Shetty Breakdown of academic impact, for papers by Michaela K. Keck Breakdown of academic impact, for papers by Gustavo Dix Junqueira Pinto Breakdown of academic impact, for papers by Hui Yi Chew